Dr. Heather Sheardown
Professor, Faculty of Engineering, McMaster University
Scientific Director, C20/20 Innovation Hub
Tier 1 Canada Research Chair in Ophthalmic Biomaterials
Sheardown is a Fellow of the Canadian Academy of Engineering, the American Institute of Medical and Biological Engineers, and the International Union of Societies of Biomaterials and Engineering. She has an international reputation for her research on ophthalmic biomaterials, including her innovative work on the development of new materials for artificial cornea and ophthalmic drug delivery. Sheardown has published extensively and holds several peer reviewed grants. She holds numerous patents on materials and drug delivery systems for treating conditions in the eye including several patents in conjunction with companies for the development of specific products and a recently granted patent on mucoadhesive micelles for treatment of dry eye. These micelles are the subject of a spin out company, 20/20 OptimEyes, which is focused on formulating the micelles with cyclosporine A for the treatment of dry eye disease. Sheardown also currently leads a large Ontario Research Fund (ORF) project specifically aimed at the development and testing of ocular drug delivery systems for the front and back of the eye, targeting conditions including dry eye disease, glaucoma and age related macular degeneration. Sheardown has worked extensively with major ophthalmic materials companies including Vistakon, CIBA Vision, Coopervision, AMO, Eyegate, Interface Biologics Inc. and Mannin Research Inc. Sheardown has consulted for Health Canada as an expert witness in the field of biomaterials. She has participated on several peer review panels for NSERC, CIHR and the National Science Foundation. Sheardown is a member of the International Society for Contact Lens Research as well as the Association for Research in Vision and Ophthalmology and the International Society for Eye Research. She has an active and vibrant research group of 10 graduate students and postdoctoral fellows. Sheardown has recently received funding to use the patented micelle technology as a vehicle for prophylactic drug delivery to the nose and lung. If successful, this technology will be an important line of defence in the fight against Covid-19.
Dr. Naveed Yasin, 2019
Hannah Mann - Summer student 2020